For children and adults with difficult-to-treat seizures

Seizure control looks different from here

Introducing new PRIMAXA, the first and only orally disintegrating tablet (ODT) of its kind, made with the proven power of primidone for treating refractory epilepsy.

A new and different option for families

PRIMAXA ODT is specifically designed for children and adults who have tried other antiseizure medications that didn’t work, or who struggle with other oral medications. PRIMAXA ODT helps makes daily treatment easier, by removing the challenges that can stand in the way of accurate dosing. Here’s how.

Dissolves on the tongue

New PRIMAXA is an ODT (orally disintegrating tablet), meaning it quickly dissolves on the tongue, with no food or water needed. This easy-to-take formulation is ideal for people with swallowing issues.

Adjustable dosing

The 50-mg and 250-mg tablets are scored (have an indented line) so you can easily split them to adjust doses as prescribed.

Take anytime, anywhere

With no refrigeration, mixing, or restorage needed, PRIMAXA ODT fits any routine at home, school, work, or on-the-go.

For Caregivers

PRIMAXA ODT is now available in bubble gum flavor, a top flavor choice for kids, to help children take their medicine as directed.

Did you know?

PRIMAXA ODT is made for personalized dosing, to fit each person’s needs. Unlike generic versions, some doses are scored (indented) to make it easier to split tablets and adjust the dose as prescribed.

INDICATION AND IMPORTANT SAFETY INFORMATION View Full

WARNING: RISK OF SUICIDAL THOUGHTS AND BEHAVIORS; ABRUPT WITHDRAWAL; CNS DEPRESSION; HEMATOLOGIC ABNORMALITIES; USE IN PREGNANCY AND LACTATION; PHENYLKETONURIA; AND MAXIMUM DOSAGE LIMITATIONS

Suicidal Thoughts and Behaviors

Antiepileptic drugs (AEDs), including PrimaxaTM ODT (primidone orally disintegrating tablets), may increase the risk of suicidal thoughts or behavior. This risk is class-wide and applies to all AEDs, regardless of indication. Monitor all patients for new or worsening depression, suicidal ideation, or unusual changes in mood or behavior. Inform patients, caregivers, and families to be alert for these symptoms and to report them immediately.

Abrupt Withdrawal

Abrupt discontinuation of Primaxa ODT may result in increased seizure frequency or status epilepticus. Withdrawal should be done gradually under close medical supervision to minimize risk.

Central Nervous System Depression

Primaxa ODT can cause dose-dependent CNS depression. The most frequently reported side effects include sedation, dizziness, ataxia, vertigo, nausea, and visual disturbances. Caution patients against performing activities requiring mental alertness, such as driving or operating machinery, until they understand how the medication affects them.

Hematologic Abnormalities

Serious blood disorders have been reported with Primaxa ODT, including agranulocytosis, aplastic anemia, and red cell aplasia. Periodic complete blood counts are recommended during prolonged therapy. Megaloblastic anemia may also occur as a rare idiosyncratic reaction and typically responds to folic acid supplementation without discontinuing therapy.

Use in Pregnancy

The effects of primidone in human pregnancy are not well established. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. AEDs have been associated with an increased incidence of birth defects. Neonatal bleeding resembling vitamin K deficiency has been reported; consider vitamin K1 supplementation during the last month of pregnancy.

Use in Lactation

Primidone and its metabolites are excreted into breast milk in substantial quantities. Monitor nursing infants for signs of sedation or feeding difficulties. Discontinue breastfeeding if adverse effects are observed.

Phenylketonuria Warning

Primaxa ODT contains aspartame, a source of phenylalanine. Use with caution in patients with phenylketonuria.

Maximum Dosage Limitation

The total daily dose of Primaxa ODT should not exceed 2 grams. Therapeutic effects may take several weeks to be fully realized. Patients on long-term treatment should undergo periodic monitoring, including bloodwork and metabolic panels (e.g., SMA-12) every 6 months.

Adverse Reactions

The most common side effects include nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, sexual dysfunction, diplopia, nystagmus, drowsiness, and morbilliform skin eruptions. Early side effects such as ataxia and vertigo tend to resolve with continued therapy or dose reduction. Rare but serious events include dermatologic reactions and hematologic abnormalities. Most adverse events are dose-related and may subside with dosage adjustment or continued use.

Please see full Prescribing Information for additional safety and dosing information.